Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.
How this was made
The 30-second read
Why it matters
The Phase II AUD readout provides statistically significant efficacy signals on both FDA-relevant drinking measures and an objective PEth biomarker, supporting continued development and endpoint discussions for Phase III and potential registration.
Market read
Traders can reassess pemvidutide’s probability of progressing to Phase III and the likely endpoint strategy (WHO risk-drinking-level vs zero heavy drinking days) based on the reported p-values and biomarker results.
What to watch
Safety includes serious adverse events (breast cancer, hyponatremia) and tolerability comparisons across trials are limited; placebo effects in patient-reported outcomes are acknowledged, so traders may weight PEth more heavily.
Background
Altimmune is advancing pemvidutide in alcohol use disorder (AUD) and has separate programs in metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease.
Ticker impact
Altimmune reported pemvidutide Phase II AUD results, including a 64.4% vs 34.8% WHO risk-drinking-level reduction and p=0.0049.
Near-term upside bias as traders price higher clinical/regulatory odds, tempered by still-exploratory liver findings and safety monitoring.
The article discloses multiple statistically significant endpoints (WHO risk drinking, zero heavy drinking days, PEth reduction) plus generally tolerable safety, which are material for biotech valuation. However, it is Phase II data with exploratory liver subgroup signals and no FDA decision yet.
Market effects
Strengthens sentiment for GLP-1 or incretin-adjacent and liver-metabolism drug developers pursuing alcohol use disorder and liver fibrosis endpoints, though this is company-specific.
Limited direct regional impact; primarily US biotech clinical-development sentiment.
AUD endpoint framing (WHO risk drinking vs zero heavy drinking days) may influence how global regulators interpret similar trials.
Counterpoint
Despite significant endpoints, the liver-related findings are exploratory and the AUD Phase III program is expected to be smaller and shorter, leaving uncertainty around registrational strength.
Key entities
- companyAltimmune
Clinical-stage biopharmaceutical company developing pemvidutide for AUD and liver/metabolic indications.
- drugpemvidutide
Investigational therapy reported to meet Phase II AUD endpoints and show PEth and weight improvements.
- regulatoryFDA Fast Track designation
Management states pemvidutide has Fast Track designation for AUD.
